Mirion reported third-quarter organic orders growth of 62% and organic revenue growth of 6.5%, with nuclear power up 14%. Management sees durable nuclear demand and normalization across medical markets.
MIR · Mirion Technologies, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Mirion Technologies, Inc. raised full-year 2026 revenue growth guidance to 24% to 25%, organic revenue growth guidance to 7% to 8%, and adjusted free cash flow guidance to $170 million to $185 million, while withdrawing its previously announced 2028 margin target.
Mirion Technologies reported third-quarter revenues of $277.8 million, up from $223.1 million, net income of $7.8 million versus $3.1 million, and backlog of $1,248.2 million at September 30, 2026. Nuclear & Safety generated 69.8% of quarterly revenue.
Mirion Technologies, Inc. reported third-quarter revenue of $277.8 million, up 24.5%, and Adjusted EBITDA of $64.8 million, up 23.7%. It revised 2026 revenue growth guidance to approximately 24% – 25%.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. Mirion reported Q2 revenue up 19.7% to $266.8M with adjusted EBITDA up 27.5% and reaffirmed full-year 2026 guidance, while Q2 orders grew 40% to $291M with backlog up nearly 40% year-over-year, but the medical segment saw end-market guides lowered and a Chinese new-build order was cancelled.
- + Backlog grew nearly 40% year-over-year to over $1.1 billion in Q2 2026.
- + Q2 orders grew 40% to $291M, with nuclear power orders excluding M&A up approximately 50%.
- + Q2 adjusted EBITDA grew 27.5% to $65.3M with margins expanding across both segments.
- + Company reaffirmed full-year 2026 guidance including ~22-24% revenue growth and $285-300M adjusted EBITDA.
- + Raised RTQA full-year organic growth outlook to double digits from prior mid-single-digit-plus guide.
- − Medical segment Q2 organic revenue declined 1%, below prior expectations of low-single-digit growth.
- − Lowered nuclear medicine full-year guide to mid-single digits from prior double-digit guide due to delayed hardware demand.
- − Lowered dosimetry full-year outlook to negative organic growth from prior flat guide.
- − Q2 organic revenue grew only 1%, held back by difficult comps, with first-half organic growth at 2% versus full-year guide of 5-7%.
- − Chinese new-build order cancellation booked in 2019, with potential contract negotiations ahead.
- − Nuclear power Q2 revenue was flat organically as growth in installed base and SMRs was offset by less new build revenue.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Specialty Industrial Machinery — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MIR
this stock
Mirion Technologies, Inc.
|
$4.18B | -27.2% | +7.5% | 142.0 | 14.6% |
|
GEV
GE Vernova Inc.
|
$202.10B | +16.8% | +9.0% | 20.1 | 2.8% |
|
ETN
Eaton Corp plc
|
$130.88B | +5.8% | +10.3% | 33.7 | 1.8% |
|
SMERY
Siemens Energy AG
|
$118.69B | — | — | — | 0.0% |
|
PH
Parker-Hannifin Corp
|
$117.88B | +6.4% | +18.9% | 32.1 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 16
Mirion reported third-quarter organic orders growth of 62% and organic revenue growth of 6.5%, with nuclear power up 14%. Management sees durable nuclear demand and normalization across medical markets.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MIR | -12.5% | +14.1% | +0.5% | -7.2% | -27.2% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -10.8% | +17.6% | +1.9% | -5.2% | -35.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.